Abbott–Exact Sciences, BioMarin–Amicus among deals cleared in Japan in Q1
( May 1, 2026, 07:41 GMT | Official Statement) -- MLex Summary: Abbott Laboratories’ proposed acquisition of cancer screening and diagnostics company Exact Sciences was among the mergers cleared by Japan’s competition regulator in the January–March period. The Japan Fair Trade Commission approved the deal on March 11, following notification on Feb. 12. Also on the list was BioMarin Pharmaceutical’s $4.8 billion acquisition of Amicus Therapeutics. The transaction, involving the California- and New Jersey-based companies, respectively, was notified on Feb. 28 and cleared on March 13. According to the merger clearance list published Friday, the JFTC reviewed a substantial number of transactions involving both domestic and overseas companies in the fiscal year ending March 2026.Statement is attached (in Japanese). ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.